Abnormal Homocysteine Metabolism: An Insight of Alzheimer's Disease from DNA Methylation. (8th September 2020)

• Record Type: Journal Article
• Authors: Pi, Tingting; Liu, Bo; Shi, Jingshan
• Other Names: Soto Horacio Academic Editor.
• Is Part Of: Behavioural neurology. Volume 2020(2020)
• Publication Date: 2020-09-08
• Subjects: Neuropsychology -- Periodicals; Neuropsychiatry -- Periodicals; Cognitive neuroscience -- Periodicals; 616.8005
• DOI: 10.1155/2020/8438602
• Languages: English
• ISSNs: 0953-4180

Abstract

Abstract : Alzheimer's disease (AD) is a chronic neurodegenerative disease in the central nervous system that has complex pathogenesis in the elderly. The current review focuses on the epigenetic mechanisms of AD, according to the latest findings. One of the best-characterized chromatin modifications in epigenetic mechanisms is DNA methylation. Highly replicable data shows that AD occurrence is often accompanied by methylation level changes of the AD-related gene. Homocysteine (Hcy) is not only an intermediate product of one-carbon metabolism but also an important independent risk factor of AD; it can affect the cognitive function of the brain by changing the one-carbon metabolism and interfering with the DNA methylation process, resulting in cerebrovascular disease. In general, Hcy may be an environmental factor that affects AD via the DNA methylation pathway with a series of changes in AD-related substance. This review will concentrate on the relation between DNA methylation and Hcy and try to figure out their rule in the pathophysiology of AD.